Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2020) 2020
Publication (195) 195
Newspaper Article (69) 69
Book Review (19) 19
Book Chapter (14) 14
Trade Publication Article (7) 7
Book / eBook (4) 4
Magazine Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1534) 1534
oncology (1136) 1136
index medicus (1039) 1039
female (1025) 1025
chemotherapy (950) 950
consolidation (891) 891
male (881) 881
middle aged (865) 865
hematology (827) 827
adult (805) 805
antineoplastic combined chemotherapy protocols - therapeutic use (694) 694
aged (615) 615
cancer (571) 571
treatment outcome (540) 540
consolidation chemotherapy (490) 490
consolidation therapy (412) 412
remission induction (408) 408
disease-free survival (399) 399
adolescent (395) 395
therapy (334) 334
survival (303) 303
transplantation (293) 293
prognosis (285) 285
care and treatment (267) 267
combined modality therapy (264) 264
survival analysis (258) 258
young adult (242) 242
stem-cell transplantation (240) 240
trial (237) 237
acute myelogenous leukemia (228) 228
antineoplastic combined chemotherapy protocols - adverse effects (228) 228
retrospective studies (223) 223
survival rate (223) 223
radiotherapy (219) 219
neoplasm staging (212) 212
follow-up studies (206) 206
leukemia (204) 204
patients (200) 200
cytarabine - administration & dosage (196) 196
leukemia, myeloid, acute - drug therapy (192) 192
antineoplastic agents - therapeutic use (188) 188
hematopoietic stem cell transplantation (186) 186
induction chemotherapy (186) 186
acute myeloid-leukemia (185) 185
acute myeloid leukemia (184) 184
antineoplastic combined chemotherapy protocols - administration & dosage (183) 183
hematology, oncology and palliative medicine (180) 180
transplantation, autologous (179) 179
stem cells (175) 175
remission (173) 173
medicine & public health (170) 170
risk factors (170) 170
aged, 80 and over (166) 166
recurrence (166) 166
child (165) 165
research (165) 165
induction (152) 152
cytarabine (151) 151
cisplatin (146) 146
health aspects (146) 146
stem cell transplantation (142) 142
child, preschool (141) 141
analysis (139) 139
clinical trials (138) 138
bone-marrow-transplantation (135) 135
chemoradiotherapy (128) 128
trans-retinoic acid (128) 128
lymphomas (126) 126
consolidation chemotherapy - methods (124) 124
leukemia, promyelocytic, acute - drug therapy (123) 123
risk (122) 122
immunology (121) 121
multiple myeloma (120) 120
adults (118) 118
bone-marrow transplantation (117) 117
leukemia, myeloid, acute - mortality (117) 117
leukemia, myeloid, acute - therapy (115) 115
ovarian cancer (115) 115
high-dose chemotherapy (114) 114
relapse (114) 114
bortezomib (110) 110
carboplatin (110) 110
randomized-trial (110) 110
cyclophosphamide (109) 109
children (108) 108
aml (106) 106
cyclophosphamide - administration & dosage (105) 105
infant (104) 104
medicine, general & internal (104) 104
acute nonlymphocytic leukemia (103) 103
diagnosis (103) 103
prospective studies (103) 103
maintenance chemotherapy (102) 102
minimal residual disease (102) 102
daunorubicin (100) 100
acute promyelocytic leukemia (99) 99
drug therapy (97) 97
toxicity (97) 97
etoposide - administration & dosage (95) 95
drug administration schedule (94) 94
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2036) 2036
French (18) 18
Japanese (13) 13
German (11) 11
Russian (10) 10
Chinese (7) 7
Spanish (7) 7
Korean (6) 6
Polish (2) 2
Czech (1) 1
Hungarian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
by Chiappella, Annalisa and Martelli, Maurizio and Angelucci, Emanuele and Brusamolino, Ercole and Evangelista, Andrea and Carella, Angelo Michele and Stelitano, Caterina and Rossi, Giuseppe and Balzarotti, Monica and Merli, Francesco and Gaidano, Gianluca and Pavone, Vincenzo and Rigacci, Luigi and Zaja, Francesco and D'Arco, Alfonso and Cascavilla, Nicola and Russo, Eleonora and Castellino, Alessia and Gotti, Manuel and Congiu, Angela Giovanna and Cabras, Maria Giuseppina and Tucci, Alessandra and Agostinelli, Claudio and Ciccone, Giovannino and Pileri, Stefano A and Vitolo, Umberto
The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study
by Altman, Alon D and McGee, Jacob and May, Taymaa and Lane, Kelly and Lu, Lin and Xu, Wei and Ghatage, Prafull and Rosen, Barry
Gynecologic Oncology, ISSN 0090-8258, 11/2017, Volume 147, Issue 2, pp. 257 - 261
Six cycles of consolidation chemotherapy have become the standard for ovarian cancer treatment regimen following primary cytoreduction, yet with neoadjuvant... 
ADJUVANT CHEMOTHERAPY | NEOPLASM TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | INTERVAL DEBULKING | ONCOLOGY | ADVANCED OVARIAN-CANCER | COMPLETE RESPONSE | CONSOLIDATION THERAPY | PRIMARY DEBULKING SURGERY | RANDOMIZED-TRIAL | STAGE-I | OBSTETRICS & GYNECOLOGY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Survival Rate | Consolidation Chemotherapy | Cystadenocarcinoma, Serous - drug therapy | Cytoreduction Surgical Procedures | Cystadenocarcinoma, Serous - surgery | Randomized Controlled Trials as Topic | Canada | Taxoids - administration & dosage | Organoplatinum Compounds - administration & dosage | Female | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Neoplasm Staging | Ovarian Neoplasms - drug therapy | Cohort Studies | Ovarian Neoplasms - surgery | Analysis | Adjuvant treatment | Cancer | Ovarian cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly‐diagnosed with central nervous system atypical teratoid/rhabdoid tumors: The head start III experience
by Zaky, Wafik and Dhall, Girish and Ji, Lingyun and Haley, Kelley and Allen, Jeffrey and Atlas, Mark and Bertolone, Salvatore and Cornelius, Albert and Gardner, Sharon and Patel, Ramesh and Pradhan, Kamnesh and Shen, Violet and Thompson, Stephen and Torkildson, Joseph and Sposto, Richard and Finlay, Jonathan L
Pediatric Blood & Cancer, ISSN 1545-5009, 01/2014, Volume 61, Issue 1, pp. 95 - 101
Background Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system (CNS) is a rare embryonal neoplasm of early childhood with dismal outcome and... 
teratoid/rhabdoid | tumors | clinical trials | chemotherapy | CNS tumors | stem cell transplantation | Clinical trials | Stem cell transplantation | Chemotherapy | Teratoid/rhabdoid | Tumors | SURVIVAL | teratoid | TERATOID RHABDOID TUMORS | ATRT | CHILDHOOD | CANCER | CONSORTIUM | THERAPY | ONCOLOGY | rhabdoid | PEDIATRICS | HIGH-DOSE CHEMOTHERAPY | RADIOTHERAPY | MUTATIONS | HEMATOLOGY | Consolidation Chemotherapy - methods | Humans | Rhabdoid Tumor - mortality | Child, Preschool | Infant | Male | Transplantation, Autologous | Hematopoietic Stem Cell Transplantation - mortality | Neurosurgical Procedures | Female | Induction Chemotherapy - mortality | Infant, Newborn | Consolidation Chemotherapy - mortality | Induction Chemotherapy - methods | Kaplan-Meier Estimate | Central Nervous System Neoplasms - therapy | Treatment Outcome | Combined Modality Therapy | Radiotherapy | Induction Chemotherapy - adverse effects | Rhabdoid Tumor - therapy | Disease-Free Survival | Hematopoietic Stem Cell Transplantation - methods | Consolidation Chemotherapy - adverse effects | Central Nervous System Neoplasms - mortality | Development and progression | Central nervous system | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text B-and T-lymphocyte number and function in HIV+/HIV- lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation
by Bertoli, Diego and Re, Alessandro and Chiarini, Marco and Sottini, Alessandra and Serana, Federico and Giustini, Viviana and Roccaro, Aldo M and Cattaneo, Chiara and Caimi, Luigi and Rossi, Giuseppe and Imberti, Luisa
Scientific Reports, ISSN 2045-2322, 12/2016, Volume 6, Issue 1, p. 37995
Combination of anti-retroviral therapy, high-dose chemotherapy (HCT) and autologous stem cell transplantation (ASCT) has led to an improved survival of HIV+... 
SALVAGE TREATMENT | MULTIPLE-SCLEROSIS | IMMUNODEFICIENCY-VIRUS-INFECTION | IMMUNE RECONSTITUTION | MULTIDISCIPLINARY SCIENCES | ACTIVE ANTIRETROVIRAL THERAPY | UNINFECTED PATIENTS | PERIPHERAL-BLOOD | HODGKIN-LYMPHOMA | STEM-CELL TRANSPLANTATION | HIV-ASSOCIATED LYMPHOMA | Autografts | Cell survival | Bone marrow transplantation | Recovery of function | Stem cell transplantation | Rituximab | T cell receptors | Lymphocytes T | Transplantation | Lymphoma | T-cell receptor | Chemotherapy | Lymphocytes B | Lymphocytes | Lymphomas
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
by Cook, Gordon, Prof and Williams, Cathy, MD and Brown, Julia M, Prof and Cairns, David A, PhD and Cavenagh, Jamie, Prof and Snowden, John A, Prof and Ashcroft, A John, PhD and Fletcher, Marie, BSc and Parrish, Chris, MBBS and Yong, Kwee, Prof and Cavet, Jim, PhD and Hunter, Hanna, MD and Bird, Jenny M, MD and Chalmers, Anna, BSc and O'Connor, Sheila, PhD and Drayson, Mark T, Prof and Morris, Treen C M, Prof and Natl Canc Res Inst Haematooncology and National Cancer Research Institute Haemato-oncology Clinical Studies Group
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 874 - 885
Summary Background Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined.... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE | SUPERIORITY | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | IMPACT | METAANALYSIS | ONCOLOGY | CLINICAL-TRIALS | LENALIDOMIDE | SALVAGE THERAPY | INDUCTION | MARROW TRANSPLANTATION | Recurrence | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Consolidation Chemotherapy - methods | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Multiple Myeloma - therapy | Time Factors | Adult | Female | Boronic Acids - administration & dosage | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Bortezomib | Dexamethasone - administration & dosage | Proportional Hazards Models | Thrombocytopenia - chemically induced | Disease Progression | Induction Chemotherapy - adverse effects | Retreatment | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Multiple Myeloma - genetics | Stem Cell Transplantation - adverse effects | Care and treatment | Relapse | Multiple myeloma | Clinical trials | Transplantation | Diseases | Cyclophosphamide | Chemotherapy | Hospitals | Stem cells | Dosage and administration | Product development | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Long‐term results of the combination of the N7 induction chemotherapy and the busulfan‐melphalan high dose chemotherapy
by Valteau‐Couanet, Dominique and Le Deley, Marie‐Cécile and Bergeron, Christophe and Ducassou, Stéphane and Michon, Jean and Rubie, Hervé and Le Teuff, Gwenael and Coze, Carole and Plantaz, Dominique and Sirvent, Nicolas and Bouzy, Jeanine and Chastagner, Pascal and Hartmann, Olivier
Pediatric Blood & Cancer, ISSN 1545-5009, 06/2014, Volume 61, Issue 6, pp. 977 - 981
ABSTRACT Background To evaluate long‐term survival of the first cohort of stage‐4 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of... 
Busulphan–Melphalan | neuroblastoma | high‐dose chemotherapy | Busulphan-Melphalan | High-dose chemotherapy | Neuroblastoma | STAGE-4 NEUROBLASTOMA | BONE-MARROW-TRANSPLANTATION | 13-CIS-RETINOIC ACID | RANDOMIZED-TRIAL | ONCOLOGY | PEDIATRICS | HIGH-RISK NEUROBLASTOMA | STEM-CELL TRANSPLANTATION | OF-PEDIATRIC-ONCOLOGY | MULTIVARIATE-ANALYSIS | CHILDREN OLDER | HEMATOLOGY | high-dose chemotherapy | AGE | Myeloablative Agonists - therapeutic use | Follow-Up Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Transplantation, Autologous | Consolidation Chemotherapy | Genes, myc | Busulfan - administration & dosage | Neuroblastoma - secondary | Child | Abdominal Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Remission Induction | Abdominal Neoplasms - surgery | Thoracic Neoplasms - surgery | Hepatic Veno-Occlusive Disease - chemically induced | Disease-Free Survival | Melphalan - administration & dosage | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Neuroblastoma - surgery | Thoracic Neoplasms - drug therapy | Transplantation Conditioning | Stem cells | Melphalan | Busulfan | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Standardized uptake decrease on [18 f]-fluorodeoxyglucose positron emission tomography after neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: Secondary analysis of a randomized trial for resectable stage iiia/b non-small-cell lung cancer
by Pöttgen, Christoph and Gauler, Thomas and Bellendorf, Alexander and Guberina, Maja and Bockisch, Andreas and Schwenzer, Nina and Heinzelmann, Fr Nk and Cordes, Sebastian and Schuler, Martin H and Welter, Stefan and Stamatis, Georgios and Friedel, Godehard and Darwiche, Kaid and Jöckel, Karl-Heinz and Eberhardt, Wilfried and Stuschke, Martin
Journal of Clinical Oncology, ISSN 0732-183X, 07/2016, Volume 34, Issue 21, pp. 2526 - 2533
PurposeA confirmatory analysis was performed to determine the prognostic value of metabolic response during induction chemotherapy followed by... 
SURVIVAL | F-18-FDG PET | PREOPERATIVE CHEMOTHERAPY | THERAPY | CONSOLIDATION CHEMOTHERAPY | ONCOLOGY | PHASE-III | CROSS-VALIDATION | CHEMORADIATION | INDUCTION | CONCURRENT CHEMORADIOTHERAPY | Carcinoma, Non-Small-Cell Lung - pathology | Prognosis | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Lung Neoplasms - therapy | Positron-Emission Tomography | Carcinoma, Non-Small-Cell Lung - mortality | Chemoradiotherapy | Carcinoma, Non-Small-Cell Lung - therapy | Female | Fluorodeoxyglucose F18 | Lung Neoplasms - diagnostic imaging | Neoadjuvant Therapy | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text PROCLAIM: Randomized Phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer
by Senan, Suresh and Brade, Anthony and Wang, Lu-Hua and Vansteenkiste, Johan and Dakhil, Shaker and Biesma, Bonne and Aguillo, Maite Martinez and Aerts, Joachim and Govindan, Ramaswamy and Rubio-Viqueira, Belén and Lewanski, Conrad and Gandara, David and Choy, Hak and Mok, Tony and Hossain, Anwar and Iscoe, Neill and Treat, Joseph and Koustenis, Andrew and Antonio, Bélen San and Chouaki, Nadia and Vokes, Everett
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 9, pp. 953 - 962
Purpose The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by... 
CARBOPLATIN | PLACEBO | CONCURRENT CHEST RADIATION | INDUCTION CHEMOTHERAPY | ONCOLOGY | CHEMORADIATION | CHEMORADIOTHERAPY | RADIOTHERAPY | DOCETAXEL | PACLITAXEL | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - radiotherapy | Lung Neoplasms - drug therapy | Humans | Middle Aged | Lung Neoplasms - radiotherapy | Etoposide - administration & dosage | Lung Neoplasms - pathology | Male | Consolidation Chemotherapy | Chemoradiotherapy | Cisplatin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Pemetrexed - administration & dosage | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma
by Blank, Oliver and von Tresckow, Bastian and Monsef, Ina and Specht, Lena and Engert, Andreas and Skoetz, Nicole
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2017, Volume 2017, Issue 4, p. CD007110
Background Combined modality treatment consisting of chemotherapy followed by localised radiotherapy is the standard treatment for patients with early stage... 
LONG-TERM SURVIVORS | COMBINED-MODALITY THERAPY | Humans | TRIAL COMPARING CHEMOTHERAPY | FOLLOW-UP | Hodgkin Disease [drug therapy; pathology; radiotherapy] | 2ND MALIGNANT NEOPLASMS | INVOLVED-FIELD-RADIOTHERAPY | Combined Modality Therapy [methods] | CHILDRENS ONCOLOGY GROUP | Randomized Controlled Trials as Topic | RADIATION-THERAPY | MEDICINE, GENERAL & INTERNAL | 3 CYCLES ABVD | CONSOLIDATION RADIATION | Survival Analysis | Recurrence | Hodgkin Disease - pathology | Infection - mortality | Neoplasms, Second Primary - mortality | Chemoradiotherapy | Disease Progression | Hodgkin Disease - radiotherapy | Heart Diseases - mortality | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Combined Modality Therapy - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
by Lo-Coco, Francesco and Avvisati, Giuseppe and Vignetti, Marco and Thiede, Christian and Orlando, Sonia Maria and Iacobelli, Simona and Ferrara, Felicetto and Fazi, Paola and Cicconi, Laura and Di Bona, Eros and Specchia, Giorgina and Sica, Simona and Divona, Mariadomenica and Levis, Alessandro and Fiedler, Walter and Cerqui, Elisa and Breccia, Massimo and Fioritoni, Giuseppe and Salih, Helmut R and Cazzola, Mario and Melillo, Lorella and Carella, Angelo M and Brandts, Christian H and Morra, Enrica and von Lilienfeld-Toal, Marie and Hertenstein, Bernd and Wattad, Mohammed and Lübbert, Michael and Hänel, Matthias and Schmitz, Norbert and Link, Hartmut and Kropp, Maria Grazia and Rambaldi, Alessandro and La Nasa, Giorgio and Luppi, Mario and Ciceri, Fabio and Finizio, Olimpia and Venditti, Adriano and Fabbiano, Francesco and Döhner, Hartmut and Döhner, Konstanze and Sauer, Michaela and Ganser, Arnold and Amadori, Sergio and Mandelli, Franco and Ehninger, Gerhard and Schlenk, Richard F and Platzbecker, Uwe and Study Alliance Leukemia and Grp Italiano Malattie Ematologiche and German-Austrian Acute Myeloid and German-Austrian Acute Myeloid Leukemia Study Group and Gruppo Italiano Malattie Ematologiche dell'Adulto
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
All- trans retinoic acid (ATRA) plus arsenic trioxide was found to be noninferior to ATRA plus chemotherapy, and less toxic, in the treatment of acute... 
TRIAL | FRONT-LINE THERAPY | RELAPSE | MEDICINE, GENERAL & INTERNAL | POLYMERASE-CHAIN-REACTION | ANTHRACYCLINE | CONSOLIDATION THERAPY | RISK | FUSION GENE TRANSCRIPTS | MINIMAL-RESIDUAL-DISEASE | CHEMOTHERAPY | Oxides - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Consolidation Chemotherapy | Thrombocytopenia - chemically induced | Oxides - adverse effects | Young Adult | Disease-Free Survival | Arsenicals - therapeutic use | Tretinoin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tretinoin - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Leukemia, Promyelocytic, Acute - genetics | Neutropenia - chemically induced | Arsenicals - adverse effects | Leukemia, Promyelocytic, Acute - drug therapy | Dosage and administration | Drug therapy, Combination | Research | Tretinoin | Arsenic | Toxicity | Leukemia | Liver | Arsenic trioxide | Patients | Studies | Promyeloid leukemia | Chemotherapy | Consolidation | Remission | Pharmaceutical industry | Drug therapy | Retinoic acid | Acute promyeloid leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: Results of a randomized phase III study
by Bujko, K and Wyrwicz, L and Rutkowski, A and Malinowska, M and Pietrzak, L and Kryński, J and Michalski, W and Oledzki, J and Kuśnierz, J and Zajac, L and Bednarczyk, M and Szczepkowski, M and Tarnowski, W and Kosakowska, E and Zwoliński, J and Winiarek, M and Wiśniowska, K and Partycki, M and Beczkowska, K and Polkowski, W and Styliński, R and Wierzbicki, R and Bury, P and Jankiewicz, M and Paprota, K and Lewicka, M and Ciseł, B and Skórzewska, M and Mielko, J and Bebenek, M and Maciejczyk, A and Kapturkiewicz, B and Dybko, A and Hajac, Ł and Wojnar, A and Leśniak, T and Zygulska, J and Jantner, D and Chudyba, E and Zegarski, W and Las-Jankowska, M and Jankowski, M and Kołodziejski, L and Radkowski, A and Zelazowska-Omiotek, U and Czeremszyńska, B and Kepka, L and Kolb-Sielecki, J and Toczko, Z and Fedorowicz, Z and Dziki, A and Danek, A and Nawrocki, G and Sopyło, R and Markiewicz, W and Kedzierawski, P and Wydmański, J and Albinski, J and Banaś, R and Chmielowska, E and Bal, W and Baszczyk-Mnich, J and Bialas, M and Borowiec, T and Bujko, M and Cencelewicz, A and Chomik, K and Chwalinski, M and Ciepela, I and Dupla, D and Florek, A and Górnicki, A and Jeziorski, K and Józwickil, W and Kobiela, J and Koda, M and Kolodziej, P and Kruszewski, P and Kryj, M and Kuciel-Lisiecka, G and Kwiatkowski, R and Lachowski, A and Liszka-Dalecki, P and Majewski, A and Majewski, W and Majsak, T and Maka, D and Malka, M and Mazurkiewicz, A and Morawiec, J and Nogal, E and Olejniczak, M and Olkowski, D and Ostrowska-Cichocka, K and Pietruszka, M and Piotrkowski, G and Plewicka, M and Porzuczek-Zuziak, D and Reszke, J and Rychter, A and ... and Polish Colorectal Study Group
Annals of Oncology, ISSN 0923-7534, 05/2016, Volume 27, Issue 5, pp. 834 - 842
Improvements in local control are required when using preoperative chemoradiation for cT4 or advanced cT3 rectal cancer. There is therefore a need to explore... 
Preoperative chemoradiation | Rectal cancer | Radiotherapy Dosage | Rectal Neoplasms - surgery | Humans | Middle Aged | Male | Combined Modality Therapy | Consolidation Chemotherapy | Chemoradiotherapy | Preoperative Care | Rectal Neoplasms - radiotherapy | Disease-Free Survival | Organoplatinum Compounds - administration & dosage | Female | Aged | Rectal Neoplasms - pathology | Neoplasm Staging | Rectal Neoplasms - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights